PURPOSE: Patients discontinue bortezomib treatment despite good response to the therapy because of bortezomib-induced neuropathy. Early and active dose reduction is recommended for efficacy of treatment. This study evaluates patterns of bortezomib-associated neuropathy and examines the effectiveness of dose modification on symptom management and treatment compliance. METHODS: This is a retrospective cohort study of multiple myeloma patients who received bortezomib intravenously from 2009 to 2012 at Samsung Medical Center, Seoul, Korea. Peripheral neuropathy was assessed using neurotoxicity subscale of the FACT/GOG-Ntx at daily clinical practice; physicians modified the dosage and schedule of bortezomib treatment. Mixed-effect models were used for evaluating changes of neuropathy symptoms over time. Linear spline models and multivariate logistic regression were used for testing the effectiveness of interventions. RESULTS: There were 1,060 visits of 55 multiple myeloma patients during the study period. Patients were most likely to have numbness of feet, painful burning in feet, muscle weakness, and the symptoms worsened over time (P < 0.05). For patients who received intervention (n = 32, 58.1 %), neuropathy symptoms were significantly decreased after the intervention (coefficient, -0.1 (95 % confidence interval (CI), -0.8, 0.6)). The intervention group had on average 5.19 (95 % CI, 3.79, 6.59) more bortezomib administrations and was 1.4 times more likely to complete the treatment (odds ratio, 1.40 (95 % CI, 0.31, 6.32)) than the nonintervention group. CONCLUSION: Close monitoring of peripheral neuropathy in patients receiving bortezomib is a feasible and useful way to manage neuropathy in the real world.
PURPOSE:Patients discontinue bortezomib treatment despite good response to the therapy because of bortezomib-induced neuropathy. Early and active dose reduction is recommended for efficacy of treatment. This study evaluates patterns of bortezomib-associated neuropathy and examines the effectiveness of dose modification on symptom management and treatment compliance. METHODS: This is a retrospective cohort study of multiple myelomapatients who received bortezomib intravenously from 2009 to 2012 at Samsung Medical Center, Seoul, Korea. Peripheral neuropathy was assessed using neurotoxicity subscale of the FACT/GOG-Ntx at daily clinical practice; physicians modified the dosage and schedule of bortezomib treatment. Mixed-effect models were used for evaluating changes of neuropathy symptoms over time. Linear spline models and multivariate logistic regression were used for testing the effectiveness of interventions. RESULTS: There were 1,060 visits of 55 multiple myelomapatients during the study period. Patients were most likely to have numbness of feet, painful burning in feet, muscle weakness, and the symptoms worsened over time (P < 0.05). For patients who received intervention (n = 32, 58.1 %), neuropathy symptoms were significantly decreased after the intervention (coefficient, -0.1 (95 % confidence interval (CI), -0.8, 0.6)). The intervention group had on average 5.19 (95 % CI, 3.79, 6.59) more bortezomib administrations and was 1.4 times more likely to complete the treatment (odds ratio, 1.40 (95 % CI, 0.31, 6.32)) than the nonintervention group. CONCLUSION: Close monitoring of peripheral neuropathy in patients receiving bortezomib is a feasible and useful way to manage neuropathy in the real world.
Authors: Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Annemiek Broyl; Sophie L Corthals; Joost Lm Jongen; Bronno van der Holt; Rowan Kuiper; Yvonne de Knegt; Mark van Duin; Laila el Jarari; Uta Bertsch; Henk M Lokhorst; Brian G Durie; Hartmut Goldschmidt; Pieter Sonneveld Journal: Lancet Oncol Date: 2010-09-21 Impact factor: 41.316
Authors: Bertrand Arnulf; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Helgi van de Velde; Huaibao Feng; Andrew Cakana; William Deraedt; Philippe Moreau Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941
Authors: P G Richardson; M Delforge; M Beksac; P Wen; J L Jongen; O Sezer; E Terpos; N Munshi; A Palumbo; S V Rajkumar; J L Harousseau; P Moreau; H Avet-Loiseau; J H Lee; M Cavo; G Merlini; P Voorhees; W J Chng; A Mazumder; S Usmani; H Einsele; R Comenzo; R Orlowski; D Vesole; J J Lahuerta; R Niesvizky; D Siegel; M-V Mateos; M Dimopoulos; S Lonial; S Jagannath; J Bladé; J San Miguel; G Morgan; K C Anderson; B G M Durie; P Sonneveld Journal: Leukemia Date: 2011-12-23 Impact factor: 11.528
Authors: Giampaolo Talamo; Umar Farooq; Maurizio Zangari; Jason Liao; Nathan G Dolloff; Thomas P Loughran; Elliot Epner Journal: Clin Lymphoma Myeloma Leuk Date: 2010-12
Authors: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel Journal: Br J Haematol Date: 2009-01-16 Impact factor: 6.998
Authors: Ashraf Badros; Olga Goloubeva; Jay S Dalal; Ilyas Can; Jennifer Thompson; Aaron P Rapoport; Meyer Heyman; Gorgon Akpek; Robert G Fenton Journal: Cancer Date: 2007-09-01 Impact factor: 6.860